Harbin Pharmaceutical Group Holding Co., Ltd.

What does Harbin Pharmaceutical Group own?

The group owns pharmaceutical manufacturing and distribution businesses across China, the Sanjing traditional medicine brand, the People's Tongtai pharmacy chain, and U.S. supplement retailer GNC through its subsidiary ZT Biopharmaceutical LLC.

Is Harbin Pharmaceutical Group publicly traded?

Its principal operating arm, Harbin Pharmaceutical Group Co., Ltd., trades on the Shanghai Stock Exchange under ticker 600664. The holding company itself is a state-linked mixed-ownership enterprise with CITIC Capital as a major investor.

Who founded Harbin Pharmaceutical Group?

The group was formed in 1989 through the consolidation of Harbin's state-owned pharmaceutical enterprises under the municipal government. It has no individual founders in the private-company sense.

Where is Harbin Pharmaceutical Group headquartered?

The company is headquartered in Harbin, the capital of Heilongjiang Province in northeastern China, where its manufacturing and corporate operations are concentrated.

How many brands does Harbin Pharmaceutical Group own?

The group controls a portfolio spanning dozens of domestic drug brands and product lines, anchored internationally by GNC and domestically by the Sanjing and People's Tongtai names.

Who owns Harbin Pharmaceutical Group?

Ownership combines Harbin municipal state-asset interests with CITIC Capital, the investment arm of state-owned CITIC Group, following the 2019 mixed-ownership reform. Ultimate control therefore rests with Chinese state and state-affiliated financial entities.

Does Harbin Pharmaceutical Group still own GNC?

Yes. As of November 2026, GNC remains wholly owned through ZT Biopharmaceutical LLC, which U.S. state filings list as the retailer's sole governing member. The group has held the company since October 2020.

The group's foundations lie in Harbin's state pharmaceutical sector, consolidated in 1989 into a unified enterprise grouping the city's major drug manufacturers. Its listed arm was established in the early 1990s and joined the Shanghai Stock Exchange in 1993, one of China's earlier pharmaceutical listings.

Through the 1990s and 2000s the company built a broad domestic portfolio: antibiotics and chemical drugs, traditional Chinese medicine under the Sanjing brand, over-the-counter products, distribution businesses including People's Tongtai pharmacy retail, and health supplements. For a period its brands, particularly the Sanjing calcium products, ranked among China's most advertised consumer health names.

The group's international profile changed in 2018 when it invested approximately $300 million in GNC, the American supplements retailer, gaining a roughly 40 percent stake and forming a China joint venture after CFIUS review found no unresolved national security concerns.

When the pandemic pushed GNC into Chapter 11 in June 2020, Harbin's consortium emerged as the winning bidder in the court-supervised sale. The approximately $770 million transaction closed on October 7, 2020, transferring GNC to Harbin control through a U.S. subsidiary, ZT Biopharmaceutical LLC, and ending GNC's life as a public company.

Since the acquisition the group has operated GNC as an arm's-length subsidiary headquartered in Pittsburgh. The U.S. chain has shrunk steadily, from about 5,200 stores at the bankruptcy to roughly 1,960 at the end of 2025, while franchise and international formats continue overseas. Domestically, Harbin Pharmaceutical remains a top-tier Chinese drug maker by revenue, with its listed arm generating on the order of CNY 16 billion annually.

The group's highest-profile scrutiny is geopolitical. GNC's operation of stores on U.S. military bases under Chinese state-linked ownership drew Senate attention, including a 2020 letter from Senator Marco Rubio urging CFIUS review. CFIUS had cleared the 2018 investment and maintains what GNC describes as an oversight relationship, but the ownership remains a recurring political talking point.

In China, the company has faced the standard pressures of pharmaceutical industry anti-corruption campaigns and pricing reform. The group has also dealt with product-quality incidents typical of large drug makers, handled through domestic regulatory processes without major sustained penalties.